Cooley
Marya Postner
- Deals
- 3
- Latest
- Sep 2026
- Most deals in
- Biotech
Firm
- Cooley Law firm · 2026 · 3 deals
Often works with
- Rama Padmanabhan 3 deals together
- Jenny Ge 3 deals together
- Lindsey O'Crump 2 deals together
- Joanna Zhang 2 deals together
- John DelMastro 2 deals together
- Carlos Ramirez 2 deals together
- Charlie Kim 2 deals together
- Brittany Wightman 2 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Sep 2026 | trispecific T cell-engager (TCE) asset | Chimagen Biosciences | GSK | Asset sale | Legal adviser to Chimagen Biosciences (seller) | Announced | 750.0 | Biotech+2 | GSK acquisition of trispecific T cell-engager (TCE) asset |
| May 2026 | Candid Therapeutics | – | UCB | Acquisition | Legal adviser to Candid Therapeutics (target) | Announced | 2,200.0 | Biotech+1 | UCB acquisition of Candid Therapeutics |
| Mar 2026 | Candid Therapeutics | – | – | Placement | Legal adviser to the issuer | Pending | 505.0 | Biotech+1 | Candid Therapeutics placement |
Deals where Marya Postner is named on the firm's deal team, by the firm or the press.